[1] Macisaac RJ,Thomas MC,Jerums G. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment co-existing with NIDDM (NEFRON) 11)[J]. Diabetes care,2009,32(8):1497-1502.[2] KRAMER HJ,NGUYEN QD,CURHAN G,et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.[J]. JAMA: the Journal of the American Medical Association,2003(24).[3] 瑞琴,张毅,李全民等.正常白蛋白尿的 2 型糖尿病肾病患者临床特点调查.中华糖尿病杂志,2017,9(8):494.498.[4] Spatola L,AndmUi S.Doppler ultIasound in kidney diseases:a key parameter in clinical long—term follow—up.J Ultmsound,2016,19(4):243.250.[5] Kalani A,Mohan A,Godbole MM,et al.Wilm’s tumor-1 protein levels in urinary exosomes from diabetic patients with or without proteinuria. PLoS 0ne,2013,8(3):e60177.[6] Zeravica R,Nincic B,Cabarkapa V,et al.Plasma endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus.Med Pregl,2016,69(5-6):140-145.[7] Perico N,Ruggenenti P,Remuzzi G. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease[J]. Current opinion in pharmacology,2017,33:34-40.[8] Aroor AR,Das NA,Carpenter AJ,et al.Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness,renal resistivity index and kidney injury.Cardiovasc Diabetol,2018,17 (1):108. (▲▼上下滑动查看全部内容)